Genotype-Guided CD30L Inhibitor Selection for Inflammatory Diseases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases like inflammatory bowel disease (IBD) are inadequate, particularly for patients who do not respond to anti-inflammatory therapies, leading to disease progression and the need for invasive surgery, and there is a lack of personalized therapeutic approaches to address the heterogeneous pathogenesis and clinical course of these diseases.
Innovation Solution
The use of CD30L inhibitors, targeted by genetic polymorphisms such as rs911605 and rs1006026, to treat inflammatory, fibrostenotic, and fibrotic diseases, including IBD, by administering CD30L or TL1A inhibitors based on genetic profiling, and combining these with additional therapeutic agents to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anti-inflammatory therapies (steroids and TNF inhibitors) are used as first line treatment, then initial treatment coverage is provided, but a significant number of patients experience lack of response or loss of response leading to disease progression
Solution Approach 1:
The patent applies parameter changes by transitioning from non-specific anti-inflammatory therapy to targeted CD30L inhibition based on genetic polymorphism parameters (rs911605 and rs1006026). This changes the treatment approach from a one-size-fits-all model to a genotype-driven model, improving response reliability for patients who fail standard therapy while maintaining adaptability through personalized medicine
Solution Approach 2:
The patent implements feedback by using genetic testing results to guide treatment selection. Patient genotypes are analyzed to determine eligibility for CD30L inhibitors, creating a closed-loop system where treatment decisions are based on individual biological characteristics and treatment response is monitored
2Reliability
If surgery (structureplasty or resection) is performed for patients not responding to first line therapies, then disease control is achieved, but invasive procedures cause post-operative risks for estimated third of patients
Solution Approach 1:
The patent replaces the mechanical surgical intervention with a biological/pharmacological approach. Instead of using surgery to control disease, the patent uses CD30L inhibitors that target the underlying immune pathway, substituting mechanical removal/reshaping with molecular-level intervention to achieve disease control
Solution Approach 2:
The patent applies preliminary action by identifying suitable candidates for CD30L inhibition through genetic screening before initiating treatment. This allows patients to receive targeted therapy before disease progression necessitates surgery, preventing the need for invasive procedures in the first place
3Measurement precision
If personalized medicine approach is implemented based on genotype, then treatment precision is improved, but current availability is limited with very few personalized therapies available
Solution Approach 1:
The patent applies segmentation by dividing the patient population into distinct groups based on genetic polymorphisms (rs911605 and rs1006026). This segmentation enables tailored treatment strategies for different genotype groups, improving treatment precision while the development of CD30L inhibitors increases therapy availability for these identified populations
Data Source
AI summary
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.